Creative Touch Permanent Makeup and Aesthetics

Inulin is the most well-characterised prebiotic ingredient available for topical skin use – a designation that carries a specific meaning beyond “microbiome-friendly.” Its prebiotic function is selective: S. epidermidis ferments inulin through its carbohydrase enzyme repertoire, producing short-chain fatty acids (primarily propionic and butyric acid) that lower the local skin surface pH, while S. aureus lacks the efficient carbohydrase pathways to exploit the same substrate at the same rate. The ecological consequence is a competitive environment in which inulin is simultaneously feeding the commensal and starving the pathogen – not through any direct antimicrobial activity, but through the metabolic asymmetry between two organisms competing for the same substrate.

The downstream consequences of that SCFA production sit at the intersection of three mechanisms already established in this knowledge base: acid mantle maintenance supporting KLK5 spatial gating, SCFA-driven acidification reinforcing the ecological conditions favouring S. epidermidis over S. aureus, and sustained S. epidermidis colonisation density maintaining the TLR2/ NF-κB/ hBD-2 induction circuit that constitutes the skin’s primary commensal-driven AMP defence. Inulin is therefore not simply a skin hydration ingredient with a prebiotic marketing claim. It is an upstream ecological intervention whose mechanistic reach extends into KLK5 regulation, beta-defensin expression, and S. aureus competitive suppression through a pathway that no direct-acting topical ingredient currently replicates.

Structure and source

Inulin is a polysaccharide composed of linear chains of β(2→1)-linked fructose units with a terminal glucose residue – a fructooligosaccharide (FOS) polymer. Chain length (degree of polymerisation, DP) varies by source and processing: native chicory inulin has an average DP of 10–12 fructose units; enzymatically hydrolysed short-chain variants (DP 2–8, commercially termed oligofructose or FOS) are more water-soluble and more readily fermented; high-DP variants (DP > 23, inulin HP) are less soluble but provide more sustained fermentation substrate. For topical application, the intermediate DP range (8–12) offers the best combination of formulation solubility, skin surface deposition, and fermentation accessibility.

The β(2→1) glycosidic linkage is the structural detail that determines inulin’s selectivity. Human digestive enzymes cannot cleave β(2→1) bonds – which is why inulin passes intact to the gut colon in the dietary context. At the skin surface, the same structural resistance to human enzymatic degradation means inulin is not broken down by skin surface enzymes but remains available as intact substrate for the microbial carbohydrases of organisms that express the appropriate β-fructosidase (inulinase) enzyme. S. epidermidis expresses β-fructosidase activity; S. aureus does not express equivalent carbohydrase activity at the same efficiency. This is the molecular basis of inulin’s selectivity – not active antimicrobial properties, but substrate specificity aligned with the carbohydrase repertoire of the desired commensal.

The mechanistic chain from topical inulin application to hBD-2 induction is longer than a direct-acting postbiotic like V. filiformis lysate, but it is mechanistically coherent and each step is independently supported: ^[6]

Step 1: Selective S. epidermidis fermentation. Applied to the skin surface in a formulation providing sustained availability, inulin is metabolised by S. epidermidis β-fructosidase → fructose monomer release → glycolysis and phosphoketolase pathway → short-chain fatty acid production. In skin S. epidermidis fermentation models, the dominant SCFAs produced are acetic acid (C2) and isovaleric acid (C5), with the specific profile varying by S. epidermidis strain and growth conditions – a different output to the propionate/butyrate-dominant profile characteristic of gut bacterial FOS fermentation. S. aureus, lacking efficient inulinase activity, cannot access the same substrate at the same rate – creating a metabolic advantage for S. epidermidis in an inulin-supplemented environment. The post-fermentation supernatant from S. epidermidis FOS fermentation significantly inhibits S. aureus biofilm formation, confirming that the SCFA-rich fermentation product is itself directly anti-staphylococcal beyond the competitive substrate effect alone. ^[5]

Step 2: SCFA-mediated acidification. Propionic acid (pKa 4.87) and butyric acid (pKa 4.82) deposited at the skin surface lower the local pH toward the 4.5–5.0 range that constitutes optimal acid mantle maintenance. This is not a trivial cosmetic effect. As established in the KLK5 and LEKTI entities, the skin surface pH is the primary spatial gating mechanism for KLK5 activity in the stratum corneum – LEKTI binds KLK5 tightly at pH ≤5.0 and releases it as the surface pH rises. An inulin-supplemented skin surface with active S. epidermidis fermentation is generating SCFAs that are directly supporting the LEKTI/KLK5 regulatory pH environment. The ecological intervention and the protease regulation are the same mechanism. ^[4]

Step 3: S. epidermidis density maintenance → TLR2/hBD-2 circuit. By selectively providing carbon substrate to S. epidermidis, inulin supports its colonisation density and metabolic activity at the skin surface. Maintained S. epidermidis colonisation means continuous TLR2 ligation on keratinocytes by S. epidermidis lipoteichoic acid → NF-κB activation → hBD-2 transcription – the commensal-AMP induction circuit described in the Beta-Defensins entity. Inulin does not activate this circuit directly; it maintains the microbial population whose presence is required for the circuit to function. The distinction matters for setting appropriate expectations: inulin does not deliver an immediate hBD-2 induction spike like a TLR2-activating lysate does. It sustains the ecological conditions under which the skin’s own TLR2/hBD-2 circuit operates continuously. ^[3]

Step 4: S. aureus competitive suppression. A 2025 in vitro fermentation study confirmed that inulin selectively supported S. epidermidis growth while suppressing S. aureus – with S. aureus showing significant growth reduction at 5% inulin versus controls. The mechanism of S. aureus suppression in this model is primarily competitive – reduced available carbon substrate, reduced ecological dominance against a well-nourished S. epidermidis population, and the increasing acidity of the SCFA-enriched microenvironment that S. aureus is less tolerant of than S. epidermidis. No direct anti-staphylococcal activity of inulin itself has been demonstrated; the suppression is ecological, not pharmacological. ^[5]

The secondary mechanism: hygroscopic film formation

Distinct from its prebiotic function, inulin forms a thin hygroscopic film on the skin surface through its hydroxyl group water-binding capacity. At concentrations of 2–5% in leave-on formulations, inulin contributes measurably to transepidermal water loss (TEWL) reduction – not by replacing barrier lipids (it does not penetrate the stratum corneum to any significant depth at standard molecular weights), but by maintaining a water-binding film at the surface that reduces evaporative loss.

This is a genuine secondary benefit – but it should be understood as a separate mechanism from the prebiotic function, operating at the surface rather than through the microbial ecology. The two mechanisms are additive in formulation benefit (microbiome support + surface hydration) but should not be conflated in clinical communication. A product delivering both functions through inulin is doing more than a simple humectant, but the hygroscopic film benefit does not substitute for barrier lipid repair in presentations where ceramide, fatty acid, and cholesterol deficiency is the primary barrier problem.

Butyric acid and collagen synthesis – the SCFA secondary benefit

A secondary pathway from S. epidermidis SCFA production has been characterised independently of the acid mantle acidification mechanism: butyric acid produced through inulin fermentation stimulates dermal fibroblast collagen I synthesis through histone deacetylase (HDAC) inhibition – a mechanism well-established in the gut SCFA/epigenetics literature and confirmed in skin fibroblast models. ^[1]

HDAC inhibition by butyrate increases histone acetylation at the COL1A1 and COL1A2 promoters, increasing transcriptional accessibility and collagen I mRNA output. This is a mechanistically distinct benefit from the acid mantle and AMP circuit effects – not primarily relevant to the antimicrobial and barrier-protective functions of inulin, but potentially relevant to the use of inulin-containing formulations in ageing skin where collagen I synthesis decline is a primary structural concern. The evidence here is at the mechanism-in-model stage rather than confirmed in clinical study – stated accordingly. ^[4]

Evidence quality

Inulin sits at Evidence Tier 2: mechanistically characterised with supporting in vitro fermentation data, but without a standalone RCT demonstrating clinical endpoints (SCORAD, TEWL, S. aureus colonisation density) attributable to inulin as a single active.

The strongest study currently available is a 2025 in vitro fermentation study demonstrating selective S. aureus suppression at 5% inulin. An ex vivo skin explant study (Boyd et al., referenced in secondary commercial sources) may also exist but has not been independently verified; the in vitro study is the directly citable primary reference. The SCFA acidification mechanism is confirmed in gut microbiome literature and extrapolated to skin with supporting skin-specific data; the extrapolation is mechanistically sound but should not be represented as established skin RCT evidence. ^[5]

Inulin is included as an active in several multicomponent clinical formulations where efficacy has been demonstrated (Eucerin Eczema Relief, formulations using Triple Biotic Technology incorporating inulin alongside fructose and glucose – see the 2021 SCIRP Triple Biotic Technology study), but these study results cannot be attributed to inulin alone. ^[2]

The practical clinical implication: inulin is appropriate for recommendation in AD, acne-prone, and ageing skin based on mechanistic rationale and supporting evidence. Clinical claims for inulin should be made at the mechanism level (“supports S. epidermidis colonisation,” “contributes to acid mantle maintenance”) rather than at the clinical outcome level (“reduces eczema severity,” “reduces S. aureus colonisation”) – the latter requiring RCT substantiation that has not yet been completed for inulin as a standalone active.